Form 4 for LGND LIGAND PHARMACEUTICALS INC
Accepted 2024-03-07 00:00:00 ET · period of report 2024-03-05 · accession 0001104659-24-031806 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2024-03-07 | 2024-03-05 | LGND | Sabba Stephen L | Dir | M - OptEx | $0.00 | +2,893 | 30.8K | +10% | $0 |
| D | 2024-03-07 | 2024-03-05 | LGND | Sabba Stephen L | Dir | S - Sale+OE | $74.30 | -1,893 | 28.9K | -6% | -$140.6K |
| D | 2024-03-07 | 2024-03-05 | LGND | Sabba Stephen L | Dir | M - OptEx | $0.00 | -2,893 | 419 | -87% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2024-03-05 | M | A | 2,893 | $0.00 | 30,819 | D | — | — | (F1) These securities, as represented in Column 5, include a grant of 1,142 restricted share units approved by the Board of Directors of the Company at the 2023 Meeting, which shares will vest in full on the earlier of (a) the date of the next annual meeting of the Company stockholders following the grant date or (b) on the first anniversary of the grant date. They also properly reflect adjustments from the OmniAb Inc. separation from the Issuer. The Shares referenced in Column 5 of Table I as disposed of on the Form 4 filed 5/10/23 for this Reporting Person inadvertently failed correctly to reflect those adjustments. That number should have been 26,784. |
| 2 | Common | Common Stock | 2024-03-05 | S | D | 1,893 | $74.30 | 28,926 | D | — | — | (F1) These securities, as represented in Column 5, include a grant of 1,142 restricted share units approved by the Board of Directors of the Company at the 2023 Meeting, which shares will vest in full on the earlier of (a) the date of the next annual meeting of the Company stockholders following the grant date or (b) on the first anniversary of the grant date. They also properly reflect adjustments from the OmniAb Inc. separation from the Issuer. The Shares referenced in Column 5 of Table I as disposed of on the Form 4 filed 5/10/23 for this Reporting Person inadvertently failed correctly to reflect those adjustments. That number should have been 26,784. |
| 3 | Derivative | Non-Qualified Stock Option (right to buy) | 2024-03-05 | M | D | 2,893 | $0.00 | 419 | D | $67.53 · — to 2024-06-04 | 2,893 Common Stock | (F3) This Option was previously reported on the Form 4 filed 6/6/14 as a Grant of 3,312 shares, which vested in full on April 24, 2015, at an exercise price of $67.53 per share, but was adjusted pursuant to the OmniAb Inc. separation from the Issuer. (F2) These securities, as represented in Column 5, were acquired by a grant of 3,312 shares by the Board of Directors of the Company at the 2014 Meeting. That grant vested in full on the first anniversary of the grant date or immediately (x) upon a change in control or a hostile takeover of the Company or (y) the death or permanent disability of the grantee if still serving at that time. |